Cerus (NASDAQ:CERS) vs. Femasys (NASDAQ:FEMY) Head-To-Head Comparison

Femasys (NASDAQ:FEMY) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Earnings and Valuation

This table compares Femasys and Cerus”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29 million	9.08	-$18.63 million	($3.53)	-0.70
Cerus	$206.13 million	2.56	-$15.63 million	($0.03)	-87.33

Cerus has higher revenue and earnings than Femasys. Cerus is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Femasys and Cerus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1	0	3	0	2.50
Cerus	1	1	3	0	2.40

Femasys presently has a consensus target price of $50.00, suggesting a potential upside of 1,916.13%. Cerus has a consensus target price of $5.25, suggesting a potential upside of 100.38%. Given Femasys’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Femasys is more favorable than Cerus.

Volatility & Risk

Femasys has a beta of -2.07, suggesting that its share price is 307% less volatile than the S&P 500. Comparatively, Cerus has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500.

Profitability

This table compares Femasys and Cerus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Cerus	-3.06%	-10.19%	-3.14%

Institutional and Insider Ownership

65.3% of Femasys shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 7.7% of Femasys shares are owned by insiders. Comparatively, 5.3% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Cerus beats Femasys on 8 of the 13 factors compared between the two stocks.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.